尼拉巴里和晚期卵巢癌:非BRCA突变环境中的一个灯塔
Mauro Francesco Pio Maiorano1, Brigida Anna Maiorano2, Annalucia Biancofiore3
1Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", 70126 Bari, Italy.
Pharmaceuticals (Basel, Switzerland)
|September 28, 2023
概括
尼拉巴是一种PARP抑制剂,已被批准用于卵巢癌的维持疗法. 本综述详细介绍了其药理学,试验数据和卵巢癌治疗的未来方向.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 卵巢癌 (OC) 是女性癌症死亡的主要原因.
- 多 (ADP-ribose) 聚合酶抑制剂 (PARPis) 在化疗后显著改善了转移性OC的维持疗法.
- 尼拉帕里布是批准用于OC治疗的关键PARPi.
研究的目的:
- 审查尼拉帕里布的药理性质.
- 总结从关键尼拉巴里布试验中获得的疗效和安全性数据.
- 讨论Niraparib在OC治疗中的未来发展.
主要方法:
- 关于niraparib的药理学的综合文献综述.
- 来自主要临床试验的数据分析,支持尼拉帕里布的批准.
- 讨论监管状况和未来的研究方向.
主要成果:
- 尼拉帕里布是第一个被批准用于第一线维护治疗的PARPi,用于敏感性OC患者,无论BRCA突变状态如何.
- 随后的批准和限制已经改进了其在二线设置中的使用.
- 在相关OC患者群体中建立了有效性和安全性概况.
结论:
- 尼拉帕里布代表了卵巢癌维持疗法的重大进展.
- 了解它的特性和试验结果对于最佳的临床应用至关重要.
- 目前正在进行的研究将进一步定义niraparib在治疗卵巢癌中的作用.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


